Trubion Pharmaceuticals, Inc. announced today presentation of preclinical data regarding its SCORPION(TM) multispecific therapeutic technology at the 100th Annual Meeting of the American Association of Cancer Research (AACR) in Denver
SEATTLE, WA, USA | April 22, 2009 | Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced today presentation of preclinical data regarding its SCORPION(TM) multispecific therapeutic technology at the 100th Annual Meeting of the American Association of Cancer Research (AACR) in Denver. The data presented demonstrated the selectivity and high potency of the bispecific CD79BxDR SCORPION molecule, its differentiation from monospecific approaches, and its potential as a therapeutic for B-cell depletion, particularly in diseases refractory to CD20-targeted therapies.
CD79BxDR SCORPION molecule: a single-chain, bispecific immunotherapeutic with potent in vitro activity against B-cell lymphoma
B-cell depletion with agents such as Rituxan(R) has proven successful in the treatment of hematological malignancies in the clinic, but patients still relapse and become refractory. Strategies to improve efficacy of B-cell directed therapies include boosting the cytotoxicity of agents and expanding to targets beyond CD20.
The objective of this preclinical model was to evaluate Trubion’s SCORPION multispecific therapeutic as a next-generation candidate for oncology. An optimal bispecific molecule was identified that demonstrated highly potent activities against B-cell lymphoma cells in vitro.
The CD79BxDR SCORPION can bind to two different targets: CD79B, a lineage-restricted component of the B-cell antigen receptor, and HLA-DR, an HLA Class II molecule. Target binding by the SCORPION molecule has an affinity similar to Trubion’s Small Modular Immunopharmaceutical (SMIP(TM)) proteins or monoclonal antibodies against the same target, but can bind both targets simultaneously. Results showed the CD79BxDR SCORPION molecule elicited strong Antibody-Dependent Cellular Cytotoxicity (ADCC) as well as highly potent direct killing, confirming the ability of Trubion’s SCORPION molecules to retain key effector functions that are known to be related to efficacy of monoclonal antibodies. In addition, the data also demonstrated in assays against the NHL-derived DoHH2 cell line, that Trubion’s SCORPION multispecific therapeutic was 100 times more potent than both rituximab and the combination of the individual mono-specific SMIP molecules against the respective CD79B and HLA-DR targets. This enhanced potency was shown to be restricted to the depletion of B-cells when in the presence of T cells, as 48 hour incubation with primary human peripheral blood mononuclear cells showed selective depletion of B (CD19+) but not T (CD3+) cells.
A copy of this poster presentation is available on Trubion’s website at http://investors.trubion.com/events.cfm.
Trubion’s SCORPION(TM) Therapeutics
Like Trubion’s SMIP(TM) therapeutics — single-chain polypeptides comprising one binding domain, one hinge domain and one effector domain — SCORPION therapeutics are also novel, single-chain polypeptides comprised of functional domains from naturally occurring proteins. However, SCORPION therapeutics are multispecific therapeutics that are capable of targeting two or more antigens simultaneously. Trubion’s SCORPION format provides the basis for development of single therapies that simultaneously inhibit multiple ligand/receptor interactions or that manipulate cellular signaling pathways by cross-linking multiple cell surface receptors. SCORPION therapeutics have long in vivo half-lives, can have other intact effector functions if appropriate, and have manufacturing profiles consistent with clinical and commercial development.
About Trubion
Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company’s mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy and convenience that it believes may offer improved patient experiences. Trubion’s current product candidates are novel single-chain protein, or SMIP, therapeutics, and are designed using its custom drug assembly technology. Trubion’s product pipeline includes CD20-directed SMIP therapeutics such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the company’s Wyeth collaboration. Trubion’s product pipeline also includes Trubion’s proprietary SMIP product candidate, TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies that is currently in Phase 1/2a clinical evaluation. In addition to Trubion’s current clinical stage product pipeline, the company is also developing additional product candidates that build on its product development experience. More information is available in the investors section of Trubion’s website: http://investors.trubion.com/index.cfm.
SOURCE: Trubion Pharmaceuticals, Inc.
Post Views: 60
Trubion Pharmaceuticals, Inc. announced today presentation of preclinical data regarding its SCORPION(TM) multispecific therapeutic technology at the 100th Annual Meeting of the American Association of Cancer Research (AACR) in Denver
SEATTLE, WA, USA | April 22, 2009 | Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced today presentation of preclinical data regarding its SCORPION(TM) multispecific therapeutic technology at the 100th Annual Meeting of the American Association of Cancer Research (AACR) in Denver. The data presented demonstrated the selectivity and high potency of the bispecific CD79BxDR SCORPION molecule, its differentiation from monospecific approaches, and its potential as a therapeutic for B-cell depletion, particularly in diseases refractory to CD20-targeted therapies.
CD79BxDR SCORPION molecule: a single-chain, bispecific immunotherapeutic with potent in vitro activity against B-cell lymphoma
B-cell depletion with agents such as Rituxan(R) has proven successful in the treatment of hematological malignancies in the clinic, but patients still relapse and become refractory. Strategies to improve efficacy of B-cell directed therapies include boosting the cytotoxicity of agents and expanding to targets beyond CD20.
The objective of this preclinical model was to evaluate Trubion’s SCORPION multispecific therapeutic as a next-generation candidate for oncology. An optimal bispecific molecule was identified that demonstrated highly potent activities against B-cell lymphoma cells in vitro.
The CD79BxDR SCORPION can bind to two different targets: CD79B, a lineage-restricted component of the B-cell antigen receptor, and HLA-DR, an HLA Class II molecule. Target binding by the SCORPION molecule has an affinity similar to Trubion’s Small Modular Immunopharmaceutical (SMIP(TM)) proteins or monoclonal antibodies against the same target, but can bind both targets simultaneously. Results showed the CD79BxDR SCORPION molecule elicited strong Antibody-Dependent Cellular Cytotoxicity (ADCC) as well as highly potent direct killing, confirming the ability of Trubion’s SCORPION molecules to retain key effector functions that are known to be related to efficacy of monoclonal antibodies. In addition, the data also demonstrated in assays against the NHL-derived DoHH2 cell line, that Trubion’s SCORPION multispecific therapeutic was 100 times more potent than both rituximab and the combination of the individual mono-specific SMIP molecules against the respective CD79B and HLA-DR targets. This enhanced potency was shown to be restricted to the depletion of B-cells when in the presence of T cells, as 48 hour incubation with primary human peripheral blood mononuclear cells showed selective depletion of B (CD19+) but not T (CD3+) cells.
A copy of this poster presentation is available on Trubion’s website at http://investors.trubion.com/events.cfm.
Trubion’s SCORPION(TM) Therapeutics
Like Trubion’s SMIP(TM) therapeutics — single-chain polypeptides comprising one binding domain, one hinge domain and one effector domain — SCORPION therapeutics are also novel, single-chain polypeptides comprised of functional domains from naturally occurring proteins. However, SCORPION therapeutics are multispecific therapeutics that are capable of targeting two or more antigens simultaneously. Trubion’s SCORPION format provides the basis for development of single therapies that simultaneously inhibit multiple ligand/receptor interactions or that manipulate cellular signaling pathways by cross-linking multiple cell surface receptors. SCORPION therapeutics have long in vivo half-lives, can have other intact effector functions if appropriate, and have manufacturing profiles consistent with clinical and commercial development.
About Trubion
Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company’s mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy and convenience that it believes may offer improved patient experiences. Trubion’s current product candidates are novel single-chain protein, or SMIP, therapeutics, and are designed using its custom drug assembly technology. Trubion’s product pipeline includes CD20-directed SMIP therapeutics such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the company’s Wyeth collaboration. Trubion’s product pipeline also includes Trubion’s proprietary SMIP product candidate, TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies that is currently in Phase 1/2a clinical evaluation. In addition to Trubion’s current clinical stage product pipeline, the company is also developing additional product candidates that build on its product development experience. More information is available in the investors section of Trubion’s website: http://investors.trubion.com/index.cfm.
SOURCE: Trubion Pharmaceuticals, Inc.
Post Views: 60
